Tandem stem cell rescue as consolidation therapy for high-risk neuroblastoma

Pediatric Blood and Cancer

Volumn 58, Issue 3, 2012, Pages 448-452

  Qayed, Muna ^a   Chiang, Kuang Yueh ^a   Ricketts, Richard ^a   Alazraki, Adina ^a   Tahvildari, Ali ^a   Haight, Ann ^a   George, Brad ^a   Esiashvili, Natia ^b   Katzenstein, Howard M ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

High risk neuroblastoma; Stem cell rescue; Tandem transplant

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; THIOTEPA; TOPOTECAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VEIN OCCLUSION; WHOLE BODY RADIATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; MALE; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84855820587     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23155     Document Type: Article

References (25)

1. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007;369:2106-2120.
2. Gurney JG, Davis S, Severson RK, et al. Trends in cancer incidence among children in the U.S. Cancer 1996;78:532-541.
3. Fish JD, Grupp SA. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant 2008;41:159-165.
4. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
5. Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000;18:468-476.
6. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003;21:1592-1601.
7. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group Study. J Clin Oncol 2009;27:1007-1013.
8. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000;18:2567-2575.
9. Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II Study. J Clin Oncol 2002;20:2284-2292.
10. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 2006;24:2891-2896.
11. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-1334.
12. Yu AL, Gilman A, Ozkaynak MF, et al. A phase III randomized trial of chimeric anti-GD2 antibody+GM-CSF+IL2 immunotherapy of high-risk neuroblastoma in first response: Children's Oncology Group (COG) study ANBL0032 (Abstract). J Clin Oncol 2009;27: abstr 10067.
13. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Kleinbaum DG, Klein M. Survival analysis: A self-learning text. New York, NY: Springer; 2005; 590 pp.
16. Villablanca JG, Reynolds CP, Swift PS, et al. Phase I trial of carboplatin, etoposide, melphalan and local irradiation (CEM-LI) with purged autologous marrow transplantation for children with high risk neuroblastoma. Med Pediatr Oncol 1999;33:170.
17. Kletzel M, Abella EM, Sandler ES, et al. Thiotepa and cyclophosphamide with stem cell rescue for children with consolidation therapy for high-risk neuroblastoma: A phase I/II study of the Pediatric Blood and Marrow Transplant Consortium. J Pediatr Hematol Oncol 1998;20:49-54.
18. Santana VM, Furman WL, Billups CA, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 2005;23:4023-4047.
19. Strasser S, McDonald G. Gastrointestinal and hepatic complications. In: Thomas E, Blume K, Forman S, editors. Thomas' Hematopoietic cell transplantation, 2nd edition. Malden, MA: Blackwell Science Ltd.; 1999. p 627-658.
20. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol 2005;6:649-658.
21. Kreissman SG, Villablanca J, diller L, et al. Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): A Children's Oncology Group (COGA 3973) study. J Clin Oncol 2007;25:9505.
22. Philip T, Ladenstein R, Zucker JM, et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: The LMCE2 study. Br J Cancer 1993;67:119-127.
23. Pradhan KR, Johnson CS, Vik TA, et al. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support. Pediatr Blood Cancer 2006;46:793-802.
24. Hobbie WL, Moshang T, Carlson CA, et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer 2008;51:679-683.
25. Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: A report from the Children's Oncology Group. J Clin Oncol 2009;27:85-91.